Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-001-2334
- Development stage
- Unknown
- Lead developer
- C-BIOMEX
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
CBT-001-2334 is a novel, DOTA-containing peptide-based radiotheranostic agent targeting carbonic anhydrase IX (CAIX/CA9), which is highly expressed in clear cell renal cell carcinoma (ccRCC) and other solid tumors. Developed by C-Biomex in collaboration with the University of Texas MD Anderson Cancer Center, CBT-001-2334 is designed for theranostic applications. It can be chelated with diagnostic radionuclides such as gallium-68 for positron emission tomography (PET) imaging, or therapeutic radionuclides such as lutetium-177 for targeted radionuclide therapy. Preclinical studies have demonstrated high CAIX-specific binding, rapid clearance from normal tissues, and robust anti-tumor efficacy, supporting its clinical translation for CAIX-positive ccRCC.
- Other names
- 177Lu-CBT-001-233468Ga-CBT-001-233469Ga-CBT-001-2334[177Lu]Lu-CBT-001-2334[68Ga]Ga-CBT-001-2334[69Ga]Ga-CBT-001-2334
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on CBT-001-2334.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBT-001-2334.